IL-17 drives psoriatic inflammation via distinct, target cell-specific mechanisms

Psoriasis is a chronic inflammatory skin disease characterized by abnormal keratinocyte proliferation and differentiation and by an influx of inflammatory cells. The mechanisms underlying psoriasis in humans and in mouse models are poorly understood, although evidence strongly points to crucial cont...

Full description

Saved in:
Bibliographic Details
Published in:Proceedings of the National Academy of Sciences - PNAS Vol. 111; no. 33; p. 11922
Main Authors: Ha, Hye-Lin, Wang, Hongshan, Pisitkun, Prapaporn, Kim, Jin-Chul, Tassi, Ilaria, Tang, Wanhu, Morasso, Maria I., Udey, Mark C., Siebenlist, Ulrich
Format: Journal Article
Language:English
Published: United States National Academy of Sciences 19-08-2014
National Acad Sciences
Series:PNAS Plus
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Psoriasis is a chronic inflammatory skin disease characterized by abnormal keratinocyte proliferation and differentiation and by an influx of inflammatory cells. The mechanisms underlying psoriasis in humans and in mouse models are poorly understood, although evidence strongly points to crucial contributions of IL-17 cytokines, which signal via the obligatory adaptor CIKS/Act1. Here we identify critical roles of CIKS/Act1-mediated signaling in imiquimod-induced psoriatic inflammation, a mouse model that shares features with the human disease. We found that IL-17 cytokines/CIKS-mediated signaling into keratinocytes is essential for neutrophilic microabscess formation and contributes to hyperproliferation and markedly attenuated differentiation of keratinocytes, at least in part via direct effects. In contrast, IL-17 cytokines/CIKS-mediated signaling into nonkeratinocytes, particularly into dermal fibroblasts, promotes cellular infiltration and, importantly, leads to enhanced the accumulation of IL-17-producing γδT cells in skin, comprising a positive feed-forward mechanism. Thus, CIKS-mediated signaling is central in the development of both dermal and epidermal hallmarks of psoriasis, inducing distinct pathologies via target cell-specific effects. CIKS-mediated signaling represents a potential therapeutic target in psoriasis.
Bibliography:Edited* by William E. Paul, National Institutes of Health, Bethesda, MD, and approved July 7, 2014 (received for review January 10, 2014)
Author contributions: H.-L.H. and U.S. designed research; H.-L.H., H.W., P.P., J.-C.K., I.T., and W.T. performed research; M.I.M. contributed new reagents/analytic tools; H.-L.H., M.I.M., M.C.U., and U.S. analyzed data; and H.-L.H., M.I.M., M.C.U., and U.S. wrote the paper.
ISSN:0027-8424
1091-6490
DOI:10.1073/pnas.1400513111